We also propose that probing a wide panel of syngeneic models and their unique tumor microenvironments with a given immunotherapy will yield insights into features (such as TIL+PD-L1+ for anti-PD1) that define responding versus non-responding tumors in humans. Here, CD274 is linked to neoplasm.